HomeREGULATORY
REGULATORY

Trazenta, Amoxicillin and Others under PMDA Risk Review
(Sep.26.2017)

The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing side effect risks for a batch of APIs including the dipeptidyl peptidase-4 (DPP-4) inhibitor Trazenta (linagliptin) and the penicillin antibiotic amoxicillin - a move that is likely to result in label changes affecting a large number of products ...
(LOG IN FOR FULL STORY)

News Calendar